Non-Hodgkin Lymphoma (NHL)

Latest News

FDA approval | Image Credit: © wladimir1804 - stock.adobe.com
FDA Approves Brentuximab Vedotin, Lenalidomide, Rituximab Triplet for R/R LBCL

February 12th 2025

Interim data from the ECHELON-3 trial previously showed that adding brentuximab vedotin to lenalidomide and rituximab improved overall survival among patients who have relapsed or refractory large B-cell lymphoma (R/R LBCL).

Non-Hodgkin Lymphoma wordcloud | Image Credit: © kalpis-stock.adobe.com.jpeg
Refining Remission Assessment in Aggressive B-Cell Lymphomas

February 7th 2025

Non-HodgkinLymphoma | Image Credit: © enterlinedesign-stock.adobe.com
SynKIR-310 Dosing for B-NHL Begins in CELESTIAL-301 Trial

January 30th 2025

Extranodal NHL is not uncommon, comprising over 30% of NHL cases | image credit: Prostock Studio - stock.adobe.com
Study Expands Knowledge of Prognostic Markers in Extranodal NHL

January 29th 2025

There remains a need for more diagnostic accuracy in cases of soft tissue NHL | image credit: phonlamaiphoto - stock.adobe.com
MRI, sIL-2R Combination Showcases Great Diagnostic Accuracy for Soft Tissue NHL

January 27th 2025

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo